Background Rhabdomyolysis is a widely recognized yet rare complication in statin use.
Rhabdomyolysis might be triggered by the prescription of high doses of statins or by statin …

Background Rhabdomyolysis is a rare but serious complication of lipid-lowering therapy.
Statin and fibrate combination increases the risk of rhabdomyolysis possibly by …

Rhabdomyolysis, a syndrome characterized by muscle necrosis with release of toxic
intracellular muscle constituents, can be a potentially fatal side effect of medical therapy …

Statins are safe, well tolerated, efficient and time tested drugs for the management of
hypercholesterolemia, and thus play a cardinal role in the management of patients with …

Rhabdomyolysis, a syndrome characterized by muscle necrosis with release of toxic
intracellular muscle constituents, can be a potentially fatal side effect of medical therapy. It …

Rhabdomyolysis (RML) is a rare and severe adverse effect of simvastatin (SIM). Several risk
factors have been described which play a role in its pathogenesis, namely age> 65 …

Rosuvastatin is a recently approved statin and used widely across the globe for primary and
secondary prevention of atherosclerotic cardiovascular heart disease. It has the highest lipid …

Rhabdomyolysis is a well-documented side effect of statin therapy. This risk is increased
with concurrent use of medications that inhibit cytochrome p450-3A4 (CYP3A4), such as …

Background: Simvastatin, a 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor, is
indicated for the treatment of hypercholesterolemia and plays an important role in both the …

Introduction Rhabdomyolysis associated with the use of pravastatin has been demonstrated
to be a rare but potentially life-threatening adverse effect of statins. Here, we report a rare …